Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over (TA1093)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 August 2025
Tebentafusp for treating advanced uveal melanoma (TA1027)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2025
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 December 2024
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 October 2024
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Diabetic retinopathy: management and monitoring (NG242)Product type:GuidanceProgramme:NICE guidelinePublished: 13 August 2024
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 27 August 2008
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 27 November 2013
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 22 May 2013
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (TA941)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Ranibizumab for treating diabetic macular oedema (TA274)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2023Published: 27 February 2013
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 September 2022
Brolucizumab for treating diabetic macular oedema (TA820)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2022
Faricimab for treating diabetic macular oedema (TA799)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Faricimab for treating wet age-related macular degeneration (TA800)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Glaucoma: diagnosis and management (NG81)Product type:GuidanceProgramme:NICE guidelineLast updated: 26 January 2022Published: 1 November 2017
Brolucizumab for treating wet age-related macular degeneration (TA672)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 February 2021
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 9 October 2019
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 July 2019
Age-related macular degeneration (NG82)Product type:GuidanceProgramme:NICE guidelinePublished: 23 January 2018
Aflibercept for treating choroidal neovascularisation (TA486)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2017
Cataracts in adults: management (NG77)Product type:GuidanceProgramme:NICE guidelinePublished: 26 October 2017
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 August 2017
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2017
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2015
Aflibercept for treating diabetic macular oedema (TA346)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 February 2014
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2011
AI technologies for detecting diabetic retinopathy (MIB265)Product type:AdviceProgramme:Medtech innovation briefingPublished: 6 July 2021
ORA G3 to measure corneal hysteresis (MIB150)Product type:AdviceProgramme:Medtech innovation briefingPublished: 18 June 2018
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)Product type:AdviceProgramme:Medtech innovation briefingPublished: 24 April 2018
Boston Keratoprosthesis Type I for corneal blindness (MIB91)Product type:AdviceProgramme:Medtech innovation briefingPublished: 18 January 2017
Icare rebound tonometer to measure intraocular pressure (MIB57)Product type:AdviceProgramme:Medtech innovation briefingPublished: 15 March 2016
AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)Product type:AdviceProgramme:Medtech innovation briefingPublished: 15 December 2015
TearLab osmolarity system for diagnosing dry eye disease (MIB47)Product type:AdviceProgramme:Medtech innovation briefingPublished: 15 December 2015
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)Product type:AdviceProgramme:Medtech innovation briefingPublished: 21 April 2015
The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)Product type:AdviceProgramme:Medtech innovation briefingPublished: 19 November 2014
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 March 2026
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 3 September 2026
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 11 November 2026
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social careStatus:Awaiting developmentExpected publication date: TBC
Timrepigene emparvovec for treating choroideremia [ID3916]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Miniature lens system implantation for advanced age-related macular degenerationStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated diabetic macular oedema [TSID10621]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lateral orbital decompressionStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating geographic atrophy [ID4041]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Teprotumumab for treating thyroid eye disease [ID6432]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
NVK-002 for treating myopia in people 3 to 17 years [TSID11961]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
AI in retinal scanning MT524 (MIB265)Status:Topic prioritisationProgramme:Medical technologies guidanceExpected publication date: TBC
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Excimer Laser Trabeculotomy (ELT) for glaucomaStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Ianalumab for treating active Sjogren's syndrome [ID6634]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veligrotug for treating thyroid eye disease [ID6636]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Satralizumab for treating thyroid eye disease [ID6648]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Monofocal intraocular lenses for cataract surgery (provisional title)Status:In developmentProgramme:Health technology evaluationExpected publication date: TBC
Vamikibart for treating uveitic macular oedema [ID6671]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ciclosporin (Vevizye) eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Deucravacitinib for treating active Sjogren's syndrome [TSID12342]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC